These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 7948099)

  • 1. Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization.
    Benhar I; Brinkmann U; Webber KO; Pastan I
    Bioconjug Chem; 1994; 5(4):321-6. PubMed ID: 7948099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38.
    Benhar I; Padlan EA; Jung SH; Lee B; Pastan I
    Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12051-5. PubMed ID: 7991583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3.
    Benhar I; Pastan I
    J Biol Chem; 1995 Oct; 270(40):23373-80. PubMed ID: 7559495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.
    Onda M; Nagata S; Tsutsumi Y; Vincent JJ; Wang Q; Kreitman RJ; Lee B; Pastan I
    Cancer Res; 2001 Jul; 61(13):5070-7. PubMed ID: 11431343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutants of immunotoxin anti-Tac(dsFv)-PE38 with variable number of lysine residues as candidates for site-specific chemical modification. 1. Properties of mutant molecules.
    Onda M; Vincent JJ; Lee B; Pastan I
    Bioconjug Chem; 2003; 14(2):480-7. PubMed ID: 12643760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.
    Bera TK; Pastan I
    Bioconjug Chem; 1998; 9(6):736-43. PubMed ID: 9815167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv.
    Reiter Y; Brinkmann U; Webber KO; Jung SH; Lee B; Pastan I
    Protein Eng; 1994 May; 7(5):697-704. PubMed ID: 8073039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Brinkmann U; Reiter Y; Jung SH; Lee B; Pastan I
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7538-42. PubMed ID: 8356052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin.
    Debinski W; Pastan I
    Bioconjug Chem; 1994; 5(1):40-6. PubMed ID: 8199233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
    Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of 111In- and 125I-labeled antiTac single-chain Fv recombinant immunotoxin.
    Kobayashi H; Kao CH; Kreitman RJ; Le N; Kim MK; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
    J Nucl Med; 2000 Apr; 41(4):755-62. PubMed ID: 10768579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A divalent recombinant immunotoxin formed by a disulfide bond between the extension peptide chains.
    Park JH; Kwon HW; Chung HK; Kim IH; Ahn K; Choi EJ; Pastan I; Choe M
    Mol Cells; 2001 Dec; 12(3):398-402. PubMed ID: 11804341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
    Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
    Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display.
    Beers R; Chowdhury P; Bigner D; Pastan I
    Clin Cancer Res; 2000 Jul; 6(7):2835-43. PubMed ID: 10914732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation.
    Brinkmann U; Di Carlo A; Vasmatzis G; Kurochkina N; Beers R; Lee B; Pastan I
    J Mol Biol; 1997 Apr; 268(1):107-17. PubMed ID: 9149145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
    Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
    Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.
    Tsutsumi Y; Onda M; Nagata S; Lee B; Kreitman RJ; Pastan I
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8548-53. PubMed ID: 10890891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein.
    Bera TK; Kennedy PE; Berger EA; Barbas CF; Pastan I
    Mol Med; 1998 Jun; 4(6):384-91. PubMed ID: 10780881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F(ab')2, and Fab' conjugated to Pseudomonas exotoxin.
    Siegall CB; Gawlak SL; Chin JJ; Zoeckler ME; Kadow KF; Brown JP; Braslawsky GR
    Bioconjug Chem; 1992; 3(4):302-7. PubMed ID: 1390985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line.
    Bruell D; Stöcker M; Huhn M; Redding N; Küpper M; Schumacher P; Paetz A; Bruns CJ; Haisma HJ; Fischer R; Finnern R; Barth S
    Int J Oncol; 2003 Oct; 23(4):1179-86. PubMed ID: 12964002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.